export const vaccinesData = [
    {
        "name": "Abrysvo™",
        "vaccineId": 1,
        "pathogenId": 1,
        "manufacturers": [
            {
                "manufacturerId": 1
            }
        ],
        "licensers": [
            {
                "licenserId": 1,
                "link": "https://www.fda.gov/media/168889/download?attachment"
            },
            {
                "licenserId": 2,
                "link": "https://www.ema.europa.eu/en/medicines/human/EPAR/abrysvo"
            }
        ],
        "licensingDates": [
            {
                "name": "FDA",
                "type": "Maternal",
                "date": "08/2023",
                "source": "https://s28.q4cdn.com/781576035/files/doc_financials/2023/ar/2023-10k.pdf"
            },
            {
                "name": "FDA",
                "type": "Older Adults",
                "date": "05/2023",
                "source": "https://s28.q4cdn.com/781576035/files/doc_financials/2023/ar/2023-10k.pdf"
            },
            {
                "name": "EMA",
                "type": "Maternal",
                "date": "08/2023",
                "source": "https://s28.q4cdn.com/781576035/files/doc_financials/2023/ar/2023-10k.pdf"
            },
            {
                "name": "EMA",
                "type": "Older Adults",
                "date": "08/2023",
                "source": "https://s28.q4cdn.com/781576035/files/doc_financials/2023/ar/2023-10k.pdf"
            }
        ],
        "approvalDate": "2023",
        "description": "Abrysvo™ is a vaccine developed by Pfizer to prevent lower respiratory tract disease caused by respiratory syncytial virus (RSV) in certain populations.",
        "introduction": {
            "General Information": {
                "Map Vaccine Preventable Diseases": "Map by disease",
                "Vaccine SmPCs (FDA, EMA, WHO, others)": "Search by disease, include combos",
                "Product profiles": "Pfizer's Abrysvo is approved for two key populations: pregnant individuals (for protecting infants) and older adults.",
                "Pipeline products - summary table": "Phase 3 studies ongoing, showing strong safety and immunogenicity data.",
                "Failed products": "None known."
            },
            "Company products, pipeline": {
                "VPD-BoD, Product presentations, Monograph": "Available as injection.",
                "Pivotal publications / data vaccines": "Published Phase 3 trials showing positive safety and efficacy results.",
                "Interviews": "Interviews with leading researchers discussing vaccine progress and approvals.",
                "Relevant literature": "Scientific articles on RSV vaccines and Abrysvo’s maternal immunization strategy.",
                "Pipeline products - detailed information (TPP)": "Phase 3 trials for additional age groups."
            }
        },
        "productProfiles": [
            {
                "type": "FDA",
                "name": "FDA-Product Profile: Abrysvo™ (Pfizer)<br/>Respiratory Syncytial Virus (RSV) vaccine",
                "composition": "Abrysvo contains RSVPreF, a protein-based vaccine designed to prevent RSV infections in targeted populations.",
                "strainCoverage": "RSV strains A and B.",
                "indication": {
                    "Pregnant individuals": "Protects infants from birth to 6 months from RSV-related lower respiratory tract disease (LRTD) when administered between 32 to 36 weeks of pregnancy.",
                    "Adults 60+": "Prevents LRTD caused by RSV in older adults."
                },
                "dosing": "Single-dose intramuscular injection.",
                "immunogenicity": "Demonstrated strong immune response in pregnant women and older adults, with high neutralizing antibody levels against RSV.",
                "efficacyEndpointsPhase3": "Reduction in RSV-related lower respiratory tract disease in infants and older adults.",
                "efficacyData": "Results show a significant decrease in severe RSV cases.",
                "durationOfProtection": "Several months, with research ongoing on long-term immunity.",
                "coAdministration": "Tested with flu vaccines; data supports co-administration in older adults.",
                "reactogenicity": "Common side effects include pain at the injection site, fatigue, headache, and muscle pain.",
                "safety": "Safe for both pregnant individuals and older adults, with no significant adverse events reported.",
                "vaccinationGoal": "Prevent severe RSV infections, particularly in vulnerable groups like newborns and the elderly.",
                "others": "FDA-approved for older adults and pregnant women. Phase 3 trials underway for expanded age groups."
            }
        ],
        "link": "https://www.pfizer.com/products/product-detail/abrysvotm",
        "lastUpdated": new Date("2024-08-01").toISOString()
    }
] 